RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ayala Pharmaceuticals Stock

Ayala Pharmaceuticals EBIT 2025

Ayala Pharmaceuticals EBIT

-21.08 M USD

Ticker

ADXS

ISIN

US0076244062

WKN

A2PGJ3

In 2025, Ayala Pharmaceuticals's EBIT was -21.08 M USD, a -9.51% increase from the -23.3 M USD EBIT recorded in the previous year.

The Ayala Pharmaceuticals EBIT history

YEAREBIT (undefined USD)
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-
2011-
2010-
2009-
2008-
2007-
2006-
2005-
2004-

Ayala Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ayala Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ayala Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ayala Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ayala Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ayala Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ayala Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ayala Pharmaceuticals’s growth potential.

Ayala Pharmaceuticals Revenue, EBIT and net profit per share

DateAyala Pharmaceuticals RevenueAyala Pharmaceuticals EBITAyala Pharmaceuticals Net Income
2025e0 undefined-21.08 M undefined-1.01 M undefined
2024e0 undefined-23.3 M undefined-955,974.76 undefined
202313,000 undefined-36.27 M undefined-48.07 M undefined
2022250,000 undefined-16.1 M undefined-15.38 M undefined
20213.24 M undefined-18.69 M undefined-17.86 M undefined
2020250,000 undefined-23.65 M undefined-26.47 M undefined
201920.88 M undefined-17.07 M undefined-16.61 M undefined
20186.06 M undefined-70.38 M undefined-66.52 M undefined
201712.03 M undefined-98.45 M undefined-93.44 M undefined
20163.99 M undefined-76.49 M undefined-73.56 M undefined
20150 undefined-48.7 M undefined-47.03 M undefined
20141 M undefined-19.54 M undefined-16.53 M undefined
20130 undefined-14.69 M undefined-20.54 M undefined
20120 undefined-12.33 M undefined-12.81 M undefined
20110 undefined-13.02 M undefined-9.65 M undefined
2010510,000 undefined-7.92 M undefined-10.81 M undefined
200930,000 undefined-4.99 M undefined930,000 undefined
200870,000 undefined-5.45 M undefined-5.42 M undefined
2007150,000 undefined-4.6 M undefined-2.46 M undefined
2006430,000 undefined-3.05 M undefined-6.2 M undefined
2005550,000 undefined-1.84 M undefined-1.81 M undefined
20040 undefined-30,000 undefined-30,000 undefined

Ayala Pharmaceuticals stock margins

The Ayala Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ayala Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ayala Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ayala Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Ayala Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ayala Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ayala Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ayala Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ayala Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ayala Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ayala Pharmaceuticals Margin History

Ayala Pharmaceuticals Gross marginAyala Pharmaceuticals Profit marginAyala Pharmaceuticals EBIT marginAyala Pharmaceuticals Profit margin
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %-278,969.21 %-369,784.6 %
20220 %-6,440 %-6,152 %
20210 %-576.85 %-551.23 %
20200 %-9,460 %-10,588 %
20190 %-81.75 %-79.55 %
20180 %-1,161.39 %-1,097.69 %
20170 %-818.37 %-776.72 %
20160 %-1,917.04 %-1,843.61 %
20150 %0 %0 %
20140 %-1,954 %-1,653 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %-1,552.94 %-2,119.61 %
20090 %-16,633.33 %3,100 %
20080 %-7,785.71 %-7,742.86 %
20070 %-3,066.67 %-1,640 %
20060 %-709.3 %-1,441.86 %
20050 %-334.55 %-329.09 %
20040 %0 %0 %

Ayala Pharmaceuticals Aktienanalyse

What does Ayala Pharmaceuticals do?

Ayala Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Ayala Pharmaceuticals's EBIT

Ayala Pharmaceuticals's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Ayala Pharmaceuticals's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Ayala Pharmaceuticals's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Ayala Pharmaceuticals’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Ayala Pharmaceuticals stock

How much did Ayala Pharmaceuticals achieve in EBIT for the current year?

In the current year, Ayala Pharmaceuticals has achieved an EBIT of -21.08 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Ayala Pharmaceuticals.

How has the EBIT of Ayala Pharmaceuticals developed in recent years?

The EBIT of Ayala Pharmaceuticals has increased by -9.511% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Ayala Pharmaceuticals?

The EBIT of Ayala Pharmaceuticals is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Ayala Pharmaceuticals pay?

Over the past 12 months, Ayala Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ayala Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Ayala Pharmaceuticals?

The current dividend yield of Ayala Pharmaceuticals is .

When does Ayala Pharmaceuticals pay dividends?

Ayala Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ayala Pharmaceuticals?

Ayala Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Ayala Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ayala Pharmaceuticals located?

Ayala Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ayala Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ayala Pharmaceuticals from 7/21/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/21/2025.

When did Ayala Pharmaceuticals pay the last dividend?

The last dividend was paid out on 7/21/2025.

What was the dividend of Ayala Pharmaceuticals in the year 2024?

In the year 2024, Ayala Pharmaceuticals distributed 0 USD as dividends.

In which currency does Ayala Pharmaceuticals pay out the dividend?

The dividends of Ayala Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Ayala Pharmaceuticals

Our stock analysis for Ayala Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ayala Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.